RLH Equity Partners Exits Avella Specialty Pharmacy

RLH Equity Partners is pleased to announce that its portfolio company, Avella Specialty Pharmacy (“Avella”), has been acquired by a large diversified healthcare company.  Avella is a national specialty pharmacy recognized for its deep clinical knowledge and excellent customer support.  The Company serves patients with chronic and complex medical issues in 20 disease states including cancer, hepatitis C, infectious diseases, infertility, and vision impairment.   The Company provides mail order fulfillment and compounding services to patients in all 50 states.  As a result of its exceptional focus on improving the health of patients, Avella has grown to become the largest privately-held specialty pharmacy in the United States.

RLH is exceptionally proud of Avella’s success in growing and scaling its business while delivering superior customer service.  This two-part achievement is reflected in the Company’s 97% overall patient satisfaction rating and Avella’s recognition on the Inc. 5000 fastest growing private companies list for 10 consecutive years. The Company grew revenue by over $1.4 billion during its partnership with RLH, with over 90% of that increase coming via organic growth.  We congratulate founder John Musil, CEO Rebecca Shanahan, RLH managing directors Rob Zielinski and Ken Hubbs, and the entire Avella organization on their achievements and wish the Company continued success in the future.

Representative news articles regarding the acquisition can be found at:

Bloomberg News – Avella
Business Journal – Avella